{"name": "Facet Biotech",
 "permalink": "facet-biotech",
 "crunchbase_url": "http://www.crunchbase.com/company/facet-biotech",
 "homepage_url": "http://www.facetbiotech.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2008,
 "founded_month": 7,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(650) 454-1000",
 "description": "",
 "created_at": "Wed Mar 10 10:53:41 UTC 2010",
 "updated_at": "Wed Aug 24 02:26:22 UTC 2011",
 "overview": "\u003Cp\u003EFacet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology drugs. Facet was formed through a spin-off of the biotechnology segment of PDL BioPharma, Inc., which was completed on December 18, 2008. It was subsequently acquired by \u003Ca href=\"/company/abbott-labs\" title=\"Abbott Labs\" rel=\"nofollow\"\u003EAbbott Labs\u003C/a\u003E. The company is headquartered in Redwood City, California.\u003C/p\u003E\n\n\u003Cp\u003EIts products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I/II clinical studies, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases; and TRU-016, a small modular immunopharmaceutical protein therapeutic in Phase I clinical studies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin\u0026#8217;s lymphoma, as well as autoimmune and inflammatory disease indications. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; and Trubion Pharmaceuticals, Inc. Facet Biotech Corporation also has license agreements with Abbott Laboratories, Inc.; Actinium Pharmaceuticals, Inc.; Genentech, Inc.; Ophthotech Corporation; Progenics Pharmaceuticals, Inc.; and Seattle Genetics, Inc. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[115,
       90],
      "assets/images/resized/0007/9791/79791v1-max-150x150.jpg"],
     [[115,
       90],
      "assets/images/resized/0007/9791/79791v1-max-250x250.jpg"],
     [[115,
       90],
      "assets/images/resized/0007/9791/79791v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Faheem",
      "last_name": "Hasnain",
      "permalink": "faheem-hasnain",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": 450000000.0,
   "price_currency_code": "USD",
   "term_code": null,
   "source_url": "http://www.fiercebiotech.com/story/breaking-news-abbott-buys-facet-biotech-450m/2010-03-09?utm_medium=rss\u0026utm_source=rss",
   "source_description": "Abbott buys Facet Biotech for $450M",
   "acquired_year": 2010,
   "acquired_month": 3,
   "acquired_day": 9,
   "acquiring_company":
    {"name": "Abbott Labs",
     "permalink": "abbott",
     "image":
      {"available_sizes":
        [[[149,
           69],
          "assets/images/resized/0002/9704/29704v2-max-150x150.png"],
         [[149,
           69],
          "assets/images/resized/0002/9704/29704v2-max-250x250.png"],
         [[149,
           69],
          "assets/images/resized/0002/9704/29704v2-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1500 Seaport Blvd",
    "address2": "",
    "zip_code": "94063",
    "city": "Redwood City",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        92],
       "assets/images/resized/0007/9790/79790v1-max-150x150.jpg"],
      [[250,
        154],
       "assets/images/resized/0007/9790/79790v1-max-250x250.jpg"],
      [[450,
        277],
       "assets/images/resized/0007/9790/79790v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}